HC Wainwright Has Positive Outlook of CTMX FY2024 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Investment analysts at HC Wainwright lifted their FY2024 earnings per share estimates for CytomX Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will earn $0.14 per share for the year, up from their previous forecast of ($0.11). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.12) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. During the same quarter in the prior year, the company earned $0.04 EPS.

CytomX Therapeutics Stock Down 2.9 %

CytomX Therapeutics stock opened at $1.01 on Wednesday. The firm has a fifty day simple moving average of $1.13 and a two-hundred day simple moving average of $1.46. CytomX Therapeutics has a twelve month low of $0.98 and a twelve month high of $5.85. The company has a market capitalization of $79.04 million, a PE ratio of 6.03 and a beta of 1.06.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors have recently bought and sold shares of CTMX. Assenagon Asset Management S.A. lifted its position in CytomX Therapeutics by 206.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after purchasing an additional 833,825 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in CytomX Therapeutics during the 1st quarter valued at $124,000. Acadian Asset Management LLC grew its holdings in CytomX Therapeutics by 1.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock worth $5,863,000 after acquiring an additional 44,640 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of CytomX Therapeutics in the first quarter valued at about $57,000. Finally, Candriam S.C.A. bought a new position in shares of CytomX Therapeutics during the second quarter valued at about $256,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.